公开(公告)号：WO2012079026A2

公开(公告)日：2012-06-14

申请号：PCT/US2011/064245

申请日：2011-12-09

Applicant: CISCO TECHNOLOGY, INC. ,  TAYLOR, Adam Laurence ,  YOUSUF, Muhammad ,  HOLLAND, .Jr, James Ronald ,  MCGILL, Neil ,  RUSTOGI, Sudhir Kumar

Inventor： TAYLOR, Adam Laurence ,  YOUSUF, Muhammad ,  HOLLAND, .Jr, James Ronald ,  MCGILL, Neil ,  RUSTOGI, Sudhir Kumar

IPC: H04L12/26

CPC classification number: H04L45/28 ,  H04L41/0663 ,  H04L41/08

Abstract: Grouping pseudowires based on hardware interfaces and configured control paths enables improved pseudowire failover performance. Signaling status changes (e.g., from standby to active status) is facilitated by using group IDs for the pseudowire groups, thereby enabling improved failover performance when there is disruption in the network.

Abstract translation: 基于硬件接口和配置的控制路径对伪线进行分组，可实现改进的伪线故障切换性能。 通过使用伪线组的组ID来促进信令状态改变（例如从备用状态改变到活动状态），从而当网络中断时能够提高改进的故障转移性能。

公开(公告)号：WO2012042539A3

公开(公告)日：2012-05-31

申请号：PCT/IN2011000669

申请日：2011-09-27

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  TREHAN SANJAY ,  DAS JAGATTARAN ,  SINGH NISHAN ,  SHARMA SUDHIR KUMAR

Inventor： JAIN RAJESH ,  TREHAN SANJAY ,  DAS JAGATTARAN ,  SINGH NISHAN ,  SHARMA SUDHIR KUMAR

IPC: C07D209/52 ,  A61K31/403 ,  A61P25/00

CPC classification number: C07D209/52 ,  A61K31/403 ,  A61K45/06

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

Abstract translation: 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法，优选通过调节神经和/或精神病学靶标（GPCR和/或非GPCR） 。

公开(公告)号：WO2012023839A3

公开(公告)日：2012-02-23

申请号：PCT/KR2011/006159

申请日：2011-08-19

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  BAGHEL, Sudhir Kumar ,  MANEPALLI, Venkateswara Rao

Inventor： BAGHEL, Sudhir Kumar ,  MANEPALLI, Venkateswara Rao

IPC: H04J11/00 ,  H04B7/26 ,  H04L1/18 ,  H04W24/00

Abstract: The present invention provides methods and apparatusfor activating and deactivating secondary cells in a carrier aggregation environment. In one embodiment, a medium access control (MAC) control element (CE) command is received from a base station for activating/deactivating a secondary cell associated with user equipment (UE). Then, the secondary cell configured for user equipment is activated/deactivated based on the MAC CE command. Further, a first uplink grant is received from the base station upon activation/deactivation of the secondary cell. Accordingly, quality information (e.g., channel quality information and sounding reference signal information) associated with the cell(s) is transmitted to the base station in the received first uplink grant over a physical uplink shared channel. Furthermore, a hybrid automatic repeat request entity associated with the secondary cell is reset.

公开(公告)号：WO2011111060A1

公开(公告)日：2011-09-15

申请号：PCT/IN2011/000140

申请日：2011-03-07

Applicant: SINGLA-PAREEK, Sneth Lata ,  SOPORY, Sudhir, Kumar ,  PAREEK, Ashwani ,  SINGH, Anil Kumar

Inventor： SINGLA-PAREEK, Sneth Lata ,  SOPORY, Sudhir, Kumar ,  PAREEK, Ashwani ,  SINGH, Anil Kumar

IPC: C12N9/88 ,  C12N15/82 ,  C12Q1/68

CPC classification number: C12N15/8271 ,  C12N9/88

Abstract: The present invention relates to CBS domain containing genes of Pokkali ( Oryza sativa L.) rice having relative expression ratio (fold change, that is, stress vs. control plant) above 2.5 folds and being capable of up-regulating expression of CBS domain containing gene when grown under 200 mM NaCl stress, and capable of substantially enhancing multiple abiotic stress tolerance of plants when overexpressed with CBS domain containing gene even under conditions of high concentration of NaCl, ZnCl 2 , and methyl viologen (MV) stress. In one embodiment, it relates to a process for isolation of CBS domain containing gene. It also relates to a method for overexpressing the CBS domain containing gene. It further relates to an overexpressed transgenic tobacco plant grown from overexpressed transgenic tobacco leaf.

Abstract translation: 本发明涉及具有高于2.5倍的相对表达比（倍数变化，即应力与对照植物）的Pokkali（Oryza sativa L.）水稻的含CBS结构域的基因，并且能够上调含有CBS结构域的CBS结构域的表达 当在200mM NaCl胁迫下生长时，即使在高浓度NaCl，ZnCl 2和甲基紫精（MV）胁迫的条件下也能够显着增强植物在含有CBS结构域的基因过表达时的多种非生物胁迫耐受性。 在一个实施方案中，其涉及用于分离含CBS结构域的基因的方法。 它还涉及一种过表达含有CBS结构域的基因的方法。 它还涉及从过表达的转基因烟叶生长的过表达的转基因烟草植物。

公开(公告)号：WO2011070592A3

公开(公告)日：2011-06-16

申请号：PCT/IN2010/000796

申请日：2010-12-09

Applicant: PANACEA BIOTEC LTD. ,  JAIN, Rajesh ,  TREHAN, Sanjay ,  THUNGATHURTHI, Sastry V.R.S. ,  NANDA, Gurmeet, Kaur ,  DAS, Jagattaran ,  MAGADI, Sitaram, Kumar ,  SHARMA, Sudhir, Kumar

Inventor： JAIN, Rajesh ,  TREHAN, Sanjay ,  THUNGATHURTHI, Sastry V.R.S. ,  NANDA, Gurmeet, Kaur ,  DAS, Jagattaran ,  MAGADI, Sitaram, Kumar ,  SHARMA, Sudhir, Kumar

IPC: C07H15/203 ,  C07D309/10

Abstract: The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2). The invention also relates to the use of compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof, for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2) and the related diseases, disorders and conditions, in a subject in need thereof.

公开(公告)号：WO2009148766A3

公开(公告)日：2010-06-10

申请号：PCT/US2009043421

申请日：2009-05-11

Applicant: GEN ELECTRIC ,  KUMAR AJITH KUTTANNAIR ,  WORDEN BRET ,  GUPTA SUDHIR KUMAR ,  BROWN THEODORE CLARK

Inventor： KUMAR AJITH KUTTANNAIR ,  WORDEN BRET ,  GUPTA SUDHIR KUMAR ,  BROWN THEODORE CLARK

IPC: B60L7/02 ,  B60L1/02

CPC classification number: B61C5/02 ,  B60L1/003 ,  B60L7/02 ,  B60L7/10 ,  B60L2200/26

Abstract: A drive system for a grid blower of a vehicle is provided. The system includes: an electrical bus, a grid of resistive elements connected to the electrical bus, the grid of resistive elements configured to thermally dissipate electrical power generated from braking of the vehicle, the electrical power being transmitted on the electrical bus to the grid of resistive elements, an electrical power modulation device configured to modify electrical power received from at least one of the electrical bus and the grid of resistive elements, and a grid blower motor coupled to an output of the electrical power modulation device, wherein a speed of the grid blower motor varies based on the electrical power that has been modified by the electrical power modulation device.

Abstract translation: 提供了一种用于车辆的电网鼓风机的驱动系统。 该系统包括：电气总线，连接到电气总线的电阻元件格栅，电阻元件格栅被配置为热散发由车辆制动产生的电力，电力在电气总线上传输到电网 电力元件，被配置为修改从电气总线和电阻元件网格中的至少一个接收的电力的电力调制装置，以及耦合到电力调制装置的输出的电网鼓风电动机，其中， 电网鼓风电机根据电力调制装置修改的电功率而变化。

公开(公告)号：WO2010058423A9

公开(公告)日：2010-05-27

申请号：PCT/IN2009/000658

申请日：2009-11-18

Applicant: PANACEA BIOTEC LTD. ,  JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KANWAR, Sandeep ,  MAGADI, Sitaram, Kumar ,  SHARMA, Sudhir, Kumar

Inventor： JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KANWAR, Sandeep ,  MAGADI, Sitaram, Kumar ,  SHARMA, Sudhir, Kumar

IPC: C07D413/10 ,  C07D413/14

Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H. influenza, Moraxella, acid-fast organisms such as Mycobacterium tuberculosis as well as Linezolid resistant species of Staphylococcus and Enterococcus.

公开(公告)号：WO2007122634A3

公开(公告)日：2007-12-21

申请号：PCT/IN2007000157

申请日：2007-04-23

Applicant: JUBILANT BIOSYS LTD ,  BALAJI VITUDUKI NARAYANA IYENG ,  PRASANNA MARAHANAKULI DATTATRE ,  SAMIRON PHUKAN ,  SUDHIR KUMAR SINGH

Inventor： BALAJI VITUDUKI NARAYANA IYENG ,  PRASANNA MARAHANAKULI DATTATRE ,  SAMIRON PHUKAN ,  SUDHIR KUMAR SINGH

IPC: C07D405/04 ,  A61K31/513 ,  A61P25/28 ,  C07D409/04

CPC classification number: C07D409/04 ,  C07D405/04

Abstract: The present invention relates to a compound of formula (I) or its stereoisomers, tautomers, solvates, hydrates, prodrugs, pharmaceutically acceptable salts or mixtures thereof, wherein A1 is nitrogen; A2 is carbon; Rl is independently selected from the group consisting of aryl or 5-6 membered heterocyclic ring system; R2 and R3 are independently selected from the group consisting of H, alkyl, substituted alkyl, alkylaryl, alkylheteroaryl, aryl, or 5-6 membered heterocyclic ring system; provided R2 or R3 is H. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or diluents. The present invention also provides a method for the prophylaxis or treatment of a medical condition associated with protein kinase, by administering a pharmaceutically effective amount of the compound of formula (I) or salts thereof.

Abstract translation: 本发明涉及式（I）化合物或其立体异构体，互变异构体，溶剂合物，水合物，前药，药学上可接受的盐或其混合物，其中A1为氮; A2是碳; R1独立地选自芳基或5-6元杂环系; R2和R3独立地选自H，烷基，取代的烷基，烷基芳基，烷基杂芳基，芳基或5-6元杂环系; 本发明还提供了包含式（I）化合物或其药学上可接受的盐与药学上可接受的载体或稀释剂组合的药物组合物。 本发明还提供了一种通过施用药学有效量的式（I）化合物或其盐来预防或治疗与蛋白激酶相关的医学病症的方法。

公开(公告)号：WO2006042245A1

公开(公告)日：2006-04-20

申请号：PCT/US2005/036474

申请日：2005-10-11

Applicant: DR. REDDY'S LABORATORIES LTD. ,  DR. REDDY'S LABORATORIES, INC. ,  MADHAVAN, Gurram Ranga ,  IQBAL, Javed ,  BHUNIYA, Debnath ,  DAS, Saibal Kumar ,  SHARMA, Sudhir Kumar ,  CHAKRABARTI, Ranjan

Inventor： MADHAVAN, Gurram Ranga ,  IQBAL, Javed ,  BHUNIYA, Debnath ,  DAS, Saibal Kumar ,  SHARMA, Sudhir Kumar ,  CHAKRABARTI, Ranjan

IPC: C07D261/08

CPC classification number: C07D275/02 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention relates to novel isoxazole compounds of formula (I) having (PPAR) agonist activity, pharmaceutical compositions containing such compounds and methods for their use.

Abstract translation: 本发明涉及具有（PPAR）激动剂活性的式（I）的异恶唑化合物，含有这些化合物的药物组合物及其用途。

公开(公告)号：US20200215128A1

公开(公告)日：2020-07-09

申请号：US16243426

申请日：2019-01-09

Applicant: Sudhir Kumar Dutta

Inventor： Sudhir Kumar Dutta

IPC: A61K35/741 ,  A61K9/00 ,  A61K31/733 ,  A61K31/732 ,  A61K9/48 ,  A61K9/50

Abstract: Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent Clostridium difficile infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.